Biologic
Similar prescribing patterns in RA seen between fellows, faculty in hospital system
PHILADELPHIA — Prescribing patterns of fellows seeing patients with rheumatoid arthritis in an urban, academic hospital system aligned with the teaching practices of faculty, according to findings presented at ACR Convergence 2022.
Biologic, conventional DMARDs achieve better results in JIA when started together
PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic disease-modifying antirheumatic drug therapy concurrently had better results than patients on other plans, according to data presented here.
Remibrutinib ‘very effective’ in treating moderate to severe chronic spontaneous urticaria
Remibrutinib appeared very effective in treating moderate to severe chronic spontaneous urticaria, with a rapid onset of action and a favorable safety profile, according to a study published in The Journal of Allergy & Clinical Immunology.
Q&A: Severe asthma treatment with biologics remains safe during COVID-19 pandemic
Patients who received biologic treatment for asthma did not experience higher SARS-CoV-2 infection rates than the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Digital measurement of asthma medication adherence, lung function useful to guide management
Evidence-based care informed by digital data collection led to a lower treatment burden among patients with severe, uncontrolled asthma, researchers reported at the European Respiratory Society International Congress.
Better use of cytokine signalizing could ‘revolutionize’ rheumatology treatment
Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
Meet the Board: Emma Guttman-Yassky, MD, PhD
“It’s a very exciting time in inflammatory skin diseases,” Emma Guttman-Yassky, MD, PhD, told Healio.
Secukinumab 300 mg viable first-line biologic in patients with psoriatic arthritis
Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.
Meet the Board: Kelly Maples, MD
Among other roles, Kelly Maples, MD, can now count herself among the members of Healio’s Allergy/Asthma Peer Perspective Board.
Treatment setting, demographics impact adherence to biologic regimens for asthma care
Factors such as administration setting and demographics impacted adherence to biologic treatment among patients with moderate to severe asthma, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.